This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $716 | Check With Us |
500mg | $1170 | Check With Us |
1g | $1755 | Check With Us |
Cat #: V3302 CAS #: 1204313-51-8 Purity ≥ 98%
Description: Icotinib HCl (formerly known as BPI-2009 HCl), the hydrochloride salt of Icotinib and an macrocyclic analog of erlotinib, is an orally bioavailable, potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 427.89 |
---|---|
Molecular Formula | C22H22ClN3O4 |
CAS No. | 1204313-51-8 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: > 30 mg/mLr |
Water: N/Ar | |
Ethanol: N/A | |
Solubility In Vivo | 0.5% CMC: 30mg/mL |
SMILES Code | O=S(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3OC)=NC=C2Cl)(NC)=O |
Synonyms | BPI-2009; BPI-2009H; BPI2009; BPI 2009; BPI2009H; BPI 2009H; Icotinib; Trade name: Conmana. |
Protocol | In Vitro | Incubation with Iconitib at 0.5 μM results in kinase activity inhibition of 91%, 99%, 96%, 61% and 61%, respectively. Iconitib inhibits the proliferation of A431 and BGC-823 A549, H460 and KB cell lines with IC50s of 1, 4.06, 12.16, 16.08, 40.71 μM. When profiled with 88 kinases, Icotinib only shows meaningful inhibitory activity to EGFR and its mutants. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation (IC50=45 nM) in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation. |
---|---|---|
In Vivo | Icotinib exhibits potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug is well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment. Icotinib inhibits tumor growth at a rate of 25.2%, 45.6% and 51.5% in the A431 cell line groups; 3.4%, 25.9% and 31.0% in the A549 cell line groups; 49.4%, 52.6% and 67.4% in the H460 cell line groups, and 30.3%, 36.4% and 46.5% in the HCT8 cell line groups, at 30, 60 and 120 mg/kg/dose, respectively. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.3370 mL | 11.6852 mL | 23.3705 mL | 46.7410 mL |
5mM | 0.4674 mL | 2.3370 mL | 4.6741 mL | 9.3482 mL |
10mM | 0.2337 mL | 1.1685 mL | 2.3370 mL | 4.6741 mL |
20mM | 0.1169 mL | 0.5843 mL | 1.1685 mL | 2.3370 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.